The Medicare agency plans to issue guidance in the coming months on how it will work with manufacturers of the first 10 high-spending prescription drugs subject to government price negotiations.
The Centers for Medicare & Medicaid Services on Wednesday released a timeline of key dates and other information as it prepares to publish on Sept. 1, 2023, the Medicare Part D drugs selected for negotiation starting in 2026.
The CMS said it plans to issue guidance and allow public comment this spring on key details of the price negotiation program, including the offer and counteroffer process between Medicare and prescription ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.